Physician profile
Alex Koper
NPI 1053324079
$4,011.43
in general payments reported to CMS, 2019-2025
31 companies · $792 in 2025
The $792 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $581 · 2021: $30.33 · 2022: $689 · 2023: $750 · 2024: $793 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $600.72 | 2024-2025 | |
| Edap Technomed INC | $410.00 | 2022-2023 | |
| Procept Biorobotics Corporation | $354.37 | 2020-2025 | Aquabeam Robotic System, Aquabeam System |
| Abbvie INC. | $312.83 | 2019-2025 | |
| Photocure INC | $250.87 | 2020-2023 | Cysview |
| Boston Scientific Corporation | $176.53 | 2019-2025 | Ams 700 |
| Progenics Pharmaceuticals, INC. | $175.91 | 2022-2023 | Pylarify |
| Palette Life Sciences, INC. | $174.69 | 2022 | |
| Medtronic, INC. | $173.47 | 2024 | Signia |
| Astellas Pharma US INC | $151.81 | 2019-2025 | Xtandi |
| Teleflex LLC | $150.73 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $137.59 | 2024-2025 | Adstiladrin |
| Immunitybio, INC. | $122.60 | 2024-2025 | |
| Biotissue Holdings INC. | $121.62 | 2023 | |
| Sumitomo Pharma America, INC. | $105.58 | 2024 | Orgovyx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $103.49 | 2019-2020 | |
| Neotract INC. | $84.67 | 2019-2020 | |
| Ambu INC. | $61.61 | 2024 | |
| Urogen Pharma, INC. | $48.93 | 2023-2025 | Jelmyto |
| C. R. Bard, INC. & Subsidiaries | $46.37 | 2020 | |
| Olympus America INC. | $43.50 | 2019 | |
| Endo Pharmaceuticals INC. | $37.29 | 2020-2021 | |
| Pfizer INC. | $32.68 | 2019-2020 | |
| Sagent Pharmaceuticals | $23.02 | 2019 | |
| Angiodynamics, INC. | $20.05 | 2025 | Nanoknife |
| Ethicon US, LLC | $18.65 | 2019 | |
| Therapeuticsmd, INC. | $17.40 | 2019 | |
| Tolmar, INC. | $16.54 | 2024 | |
| Foundation Medicine, INC. | $14.14 | 2019 | |
| Janssen Biotech, INC. | $12.66 | 2019 | |
| Cook Medical LLC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Koper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.